Clinical Trials Logo
  1. Home
  2. Hypogammaglobulinemia
  3. NCT00137748

Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients

Hypogammaglobulinemia Clinical Trial

Official title:
Does Replacement With CMVIG in Hypogammaglobulinemic Patients Decrease the Rate of Opportunistic Infections and Chronic Rejection?

Clinical Trial Summary

This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.

Clinical Trial Description

This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00137748
Study type Interventional
Source The Cleveland Clinic
Contact
Status Completed
Phase Phase 2/Phase 3
Start date January 2001
Completion date January 2006
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04502030 - Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Phase 3
Completed NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Phase 2/Phase 3
Recruiting NCT05678621 - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension Phase 2/Phase 3
Completed NCT01581593 - Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Phase 3
Completed NCT02043379 - Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates N/A
Completed NCT00138697 - Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients Phase 2/Phase 3
Not yet recruiting NCT04447937 - Immunodeficiency in MS
Completed NCT00115778 - Intravenous Immunoglobulin (IVIG) in Lung Transplantation Phase 2
Completed NCT00161993 - Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) Phase 2
Recruiting NCT05357781 - Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
Completed NCT00278954 - Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Phase 3
Completed NCT01002755 - Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 2
Recruiting NCT04283747 - Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis
Completed NCT03401268 - Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients N/A
Recruiting NCT05645107 - A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia Phase 3
Active, not recruiting NCT01981785 - Investigation of Immune Disorders and Deficiencies N/A
Completed NCT02508584 - Personalized Immunotherapeutic for Antibiotic-resistant Infection Early Phase 1